Background: The SCORing Atopic Dermatitis (SCORAD) index is used worldwide to assess the severity of atopic eczema. Patient involvement in the treatment process is of major current interest. There are very few validated patient self-assessment tools for atopic dermatitis (AD). Objective: To develop a self-assessment score for AD patients, the patient-oriented SCORAD (PO-SCORAD) based on the SCORAD index, and to assess its acceptability in a pilot study. Methods: A multicenter working group decided on the initial form of the PO-SCORAD. A prospective, single-center pilot study was then carried out to assess its acceptability and validity. A SCORAD and a PO-SCORAD were applied at baseline and after 18 days; the acceptability of the tool was assessed by questionnaire, its validity by comparing SCORAD and PO-SCORAD on both visits. Results: The study involved 15 children and 18 adults. 80% of the respondents found the questions clear and the form easy to fill in; 96% spent less than 10 min on it. A correlation was found between the SCORAD and the PO-SCORAD. Conclusion: This study shows that self-assessment is feasible in AD, and that there is a correlation between the physician and the patient scores. This study was the first step in validating the PO-SCORAD.

1.
Fennessy M, Coupland S, Popay J, et al: The epidemiology and experience of atopic eczema during childhood: a discussion paper on the implications of current knowledge for health care, public health policy and research. J Epidemiol Community Health 2000;54:581–589.
2.
Williams H, Robertson C, Stewart A, et al: Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood. J Allergy Clin Immunol 1999;103:125–138.
3.
Williams HC: Clinical practice: atopic dermatitis. N Engl J Med 2005;352:2314–2324.
4.
Leung DY, Bieber T: Atopic dermatitis. Lancet 2003;361:151–160.
5.
Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC: The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005;22:192–199.
6.
Finlay AY: Measurement of disease activity and outcome in atopic dermatitis. Br J Dermatol 1996;135:509–515.
7.
Charman CR, Williams HC: Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000;136:763–769.
8.
European Task Force on Atopic Dermatitis: Severity scoring of atopic dermatitis: the SCORAD Index. Dermatology 1993;186:23–31.
9.
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M; EASI Evaluator Group: The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001;10:11–18.
10.
Berth-Jones J: Six-Area, Six-Sign Atopic Dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996;135 (suppl 48):25–30.
11.
Kvien TK, Heiberg T: Patient perspective in outcome assessments – perceptions or something more? J Rheumatol 2003;30:873–876.
12.
Houseman TS, Patel MJ, Camacho F, Feldman SR, Fleischer AB Jr, Balkrischnan R: Use of the SA Eczema Area and Severity Index by parent caregivers: results of a validation study. Br J Dermatol 2002;147:1192–1198.
13.
Lob-Corzilius T, Böer S, Scheewe S, Wilkec K, Schon M, Schulte im Walde J, Diepgen TL, et al: The ‘Skin Detective Questionnaire’: a survey tool for self-assessment of patients with atopic dermatitis: first results of its application. Dermatol Psychosom 2004;5:141–146.
14.
Charman CR, Venn AJ, Williams HC: The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol 2004;140:1513–1519.
15.
Schmitt J, Langan S, Williams HC, European Dermato-Epidemiology Network: What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007;120:1389–1398.
16.
Sampogna F, Sera F, Mazzotti F, Pasquini P, Picardi A, Abeni D: Performance of the self-administered Psoriasis Area and Severity Index in evaluating clinical and sociodemographic subgroups of patients with psoriasis. Arch Dermatol 2003;139:353–358.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.